October 28, 2014
A third-party investigation found that Bristol-Myers K.K. most likely violated the health ministry’s ethical guidelines with its involvement in an investigator-initiated clinical trial on Sprycel (dasatinib), the company’s chronic myeloid leukemia (CML) drug. The multi-center trial was conducted to examine...read more